Related Experiment Videos
Genetic cholestasis, causes and consequences for hepatobiliary transport
Peter L M Jansen1, Ekkehard Sturm
1Department of Gastroenterology,University Hospital Groningen, The Netherlands. p.l.m.jansen@int.azg.nl
Summary
Bile salt transport is crucial for liver health, with defects causing progressive familial intrahepatic cholestasis (PFIC). Understanding these genetic disorders aids in developing targeted therapies for bile acid metabolism and liver protection.
Area of Science:
- Hepatology and Gastroenterology
- Molecular Biology
- Genetics
Background:
- Bile salts undergo efficient enterohepatic circulation, primarily absorbed in the ileum.
- Hepatic uptake and secretion involve specific transporters at sinusoidal and canalicular membranes.
- Genetic defects in canalicular secretion cause cholestasis, impacting bile flow and adaptive gene expression.
Purpose of the Study:
- To review the role of bile salt transporters in enterohepatic circulation.
- To elucidate the genetic basis and clinical manifestations of progressive familial intrahepatic cholestasis (PFIC).
- To discuss therapeutic strategies for different types of PFIC.
Main Methods:
- Review of literature on bile salt transport and genetic cholestatic diseases.
- Analysis of gene mutations associated with PFIC types 1, 2, and 3.
- Correlation of genetic defects with clinical presentation and treatment outcomes.
Main Results:
- PFIC types 1, 2, and 3 result from mutations in FIC1, BSEP, and MDR3 genes, respectively.
- PFIC type 2 (BSEP mutation) presents with permanent cholestasis and low gamma-GT.
- PFIC type 3 (MDR3 mutation) involves phospholipid transport defects, leading to toxic bile and elevated gamma-GT.
Conclusions:
- Defects in hepatobiliary transport proteins cause PFIC, a spectrum of genetic cholestatic disorders.
- Therapeutic approaches include bile diversion, ursodeoxycholic acid, and liver transplantation.
- Understanding transporter function is key to managing bile acid homeostasis and liver disease.